A phase 3 open-label study of the safety and efficacy of Adalimumab in subjects with moderate to severe Hidradenitis Suppurativa (2013–2016)
- Grant type:
- ABBVIE Pty Ltd
- Researchers:
-
-
- Funded by:
- ABBVIE Pty Ltd
